Thermo Fisher will leverage its drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics to support CSL's product portfolio
Thermo Fisher partners with CSL to address biologic therapies demand. (Credit: Thermo Fisher Scientific Inc.)
Thermo Fisher Scientific, a biotechnology company, has partnered with CSL to help meet the emerging demand for biologic therapies, and support CSL’s manufacturing objectives.
Under the partnership, the company will leverage its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics, to support CSL’s product portfolio.
Thermo Fisher Scientific executive vice president Michel Lagarde said: “We continue to invest to meet the growing need for flexible biologics capacity, and Lengnau will significantly expand our pharma services capacity and capabilities.
“This partnership clearly strengthens our unique customer value proposition, which leverages our scale and depth of capabilities for pharma and biotech customers.
“In addition to adding a high-volume production site, we can also address a broadening range of manufacturing needs for our customers, including CSL. This approach creates a win/win by making it simple for customers to start with us and stay with us as their requirements grow.”
Thermo Fisher will operate a new manufacturing facility for CSL in Lengnau, Switzerland
Thermo Fisher is expected to operate a new advanced biologics manufacturing facility in Lengnau, Switzerland, through a long-term lease agreement with CSL in place. The construction of the manufacturing site is expected to be completed in mid-2021.
Thermo Fisher said that the Lengnau site will support the manufacturing of CSL’s advanced product for haemophilia patients.
In addition, the site is designed to feature flexible bioproduction technologies, including single-use and stainless steel, to facilitate development to large-scale production. The company intends to expand the site to include additional biopharma customers.
CSL chief operating officer Paul McKenzie said: “As part of the CSL Board of Directors’ strategic review, we are in the process of transforming our end-to-end supply chain with a view to ensuring the company’s global manufacturing network is operating at a best-in-class level.
“This includes balancing internal investment with access to capabilities and capacities that are available with an experienced partner.
“Through this strategic partnership with Thermo Fisher, CSL will now be able to access a wide range of capabilities provided by a leading pharma services provider, and we are confident that the management of the Lengnau facility and team will be in the very best of hands.”